

INSTITUTIONAL RESEARCH

Biotechnology <u>UPDATE REPORT</u>

Member FINRA/SIPC

Toll-Free: 866-928-0928 ◆ www.DawsonJames.com ◆ 101 North Federal Highway - Suite 600 ◆ Boca Raton, FL 33432

Anavex Life Sciences Corp. (NASDAQ/AVXL)

BUY Rated: Reports Fiscal 1st QTR: \$15M Burn, \$143M in Cash

Anavex reported fiscal 1st Quarter (Dec. YE) with a long list of both accomplishments & pipeline updates. The company has plenty of capital, spending \$15M in the period and closing the period with \$143M in cash. We remain believers in the mechanism of action associated with ANAVEX2-73.

Investment Highlights:

A New Approach to CNS Disease. The development of Alzheimer's has been linked to different mechanisms which may trigger negative cascades. Research advances are emerging around what happens when cells undergo stress. Why do some survive, and others degenerate? One answer may relate to individual cell survival mechanisms, which in part may be associated with the role of the Sigma-1 Receptor, which is activated (an agonist) by ANAVEX2-73. It is believed that Sigma 1 can help to protect a cell from the accumulation of misfolded proteins, acting to chaperone them out of the cell. As a result, cell metabolism (oxidative stress and mitochondrial dysfunction) is kept in balance. The implications here can impact a wide range of neurodegenerative diseases, from Alzheimer's to Parkinson's, and niche orphan diseases such as Rett's syndrome, which may represent a "fast path" to establish proof of concept around Sigma 1 agonism.

Key Near-Term Pipeline Updates: (press release):

- **Alzheimer's disease:** Full data ANAVEX2-73-AD-004: Potentially pivotal Phase 2b/3 clinical trial
- Parkinson's disease dementia: Data of 48-week OLE Phase 2 study
- Parkinson's disease: Initiation of ANAVEX2-73 imaging-focused clinical trial
- Fragile X: Initiation of potentially pivotal ANAVEX2-73 Phase 2/3 clinical trial
- Schizophrenia: Initiation of ANAVEX3-71 Phase 2 clinical trial
- **New Rare disease:** Initiation of potentially pivotal ANAVEX2-73 Phase 2/3 clinical trial
- Publications: Several clinical publications involving ANAVEX2-73, ANAVEX3-71, and Rett syndrome Burden of Illness study

Valuation. Our valuation is based on our therapeutic models and associated assumptions projected to 2030. Our model assumes multiple financial raises, and as such, our share count is based on a projected, fully diluted out-year basis. Given the early nature of the company and its dependence on clinical trial outcomes in the CNS space, we apply a probability of success (50%) in our models. On top of this, we also add a 30% risk rate in our free cash flow to the Firm (FCFF), our discounted EPS (dEPS), and sum-of-the-parts (SOP) models. We equal weight and average these metrics and then round to the nearest whole number to derive our price target.

Risks to our thesis include: (1) commercial; (2) regulatory; (3) clinical; (4) market share; (5) financial; (6) investment; and (7) intellectual property.

February 7, 2022

Jason Kolbert Managing Director & Senior Analyst jkolbert@dawsonjames.com






Exhibit 1. Income Statement (\$ in thousands)

Montane March Ma	Anavex Life Sciences Corp	тепт (ф п	i mousane	us)													
Processor Proc		20104	20204	2021 A	10224	20224	30224	40224	20224	20225	2024E	20255	20265	20275	20295	20205	20205
Name	·	2019A	2020A	2021A	IQZZA	20(22A	JUZZA	4Q22A	2022A	2023L	2024L	2023L	2020L	2027L	2020L	2029L	2030L
### According Systems Property Property			-	-	-	-	-	-	-		-	-	996,342	1,332,252	1,067,282	1,244,145	1,348,343
## Control Con	Anavex2-73 AD ROW			-	-	=	=	-	=		-	-	1,235,807	1,285,239	1,103,163	1,350,272	1,606,824
Total Standord Research Control 1.00 1.0	Anavex2-73 Rett's Syndrome			-	-	=	=	-	=		28,192	71,890	586,623	747,945	915,484	933,794	952,470
***Semprend Course ***Process ***Total Course	Anavex2-73 Parkinson's Dimentia PDD				-	-	-	-		-	-	-	177,649	241,602	369,651	439,885	480,732
***Semprend Course ***Process ***Total Course	Total Draduat Payanyaa										29.402	71 900	2 006 424	2 607 027	2 455 504	3 069 006	4 200 260
**************************************											20,132	71,090	2,990,421	3,007,037	3,433,361	3,900,090	4,366,306
Males Note Males Profit Reviews (2000) Males Profit Reviews	% Crig																
Males Note Males Profit Reviews (2000) Males Profit Reviews	% Sequential Growth																
Control Revenues (1970) Control Revenues	· ·																
Total Planewask (2009)																	
Expenses		_	-	-	-	-	-	-	-	-	28.192	71.890	2.996.421	3.607.037	3,455,581	3.968.096	4.388.368
Cast of Cooks Sold (10%) Controlling and Augiliarians Americaning and Augi				I					I		20,102	,550	_,,,,,		5,100,001	3,0-00,000	.,000,000
Accounting and Author Free Amountained and Experimental Counting free Co			_	-	_	_	-	_	-	-	_	, i	223.215	261.749	217.045	259,442	295.517
Bank Changes and Interest Consusting Fee Insurance													-,		,		
Consulting Fees Investment relations Investment rel	Amortization and deprectiation	2	2	2	0	0	0	0	2	2	2	2	2	2	2	2	2
Insurance (mester relations (Logal Res) Whetangement Research and Development (Research and Development Research and Development (Research and Development Research and Development Research and Development (Research and Development Research Research and Development Research Research and Development Research Researc	Bank charges and interest																
Investor relations (agail fees	Consulting Fees																
Signate Sign	Insurance																
Management fees Registration and filing fees Registration and filing fees Registration and filing fees Registration and filing fees Research and Development 22,260 25,232 32,267 8,604 9,273 11,382 12,067 41,326 38,905 31,593 25,655 20,834 16,918 13,739 11,157 9,060 Stafface and wages Traval Wabside design and maintence General and Administrative O.847 5,857 9,205 2,915 31,85 3,903 3,317 13,329 40,000 75,000 65,600 65,650 66,307 66,870 67,639 68,311 Coper language and Administrative Oper language and Administ	Investor relations																
Office and misculations expenses Regulated and distribution Regulate	Legal fees																
Registration and filing fuee Research and Development 2 2 2 200 2 5 2 32 2 3 2 2 6 7 8 8 6 0 4 9 2 7 3 11 38 2 12 0 6 7 41 32 8 38 9 0 5 31 59 3 2 5 6 5 2 0 8 3 16 9 18 13 7 39 11 1,157 9 0.00 Statisfies and was present and administration of the statistics and mainteners of the statistics and mai	Management fees																
Research and Development 22,260 25,22 32,267 8,804 9,273 11,382 12,067 41,326 38,905 31,903 25,655 20,834 16,918 13,739 11,157 9,000 Salaries and Wages Transch Website design and maintence Centeral and Authorities and Wages Transch Website design and maintence Centeral and Authorities and Wages Transch Website design and maintence Centeral and Authorities and Wages Transch Website design and maintence Centeral and Authorities and Wages Transch Website design and maintence Centeral and Authorities and Maintenance Centeral and Authorities Centeral and Authorities Centeral and Authorities Centeral Authorities Centera	Office and miscellanous expense																
Research and Development (22,280 25,232 32,267 8,604 9,273 11,382 12,067 41,326 38,905 31,593 25,655 20,834 16,918 13,739 11,157 9,080 Wheshiel design and maintenne (26,6847 5,857 9,255 2,915 3,186 3,903 3,317 13,320 40,000 76,000 65,000 65,650 66,307 66,970 67,639 68,316 Coper flooring (20,000 10,000	Registration and filing fees																
Salaries and wages Travel WebSite design and maintence Ceneral and Administrative 6,847 5,857 9,205 2,915 3,185 3,903 3,317 13,320 40,000 75,000 66,300 66,307 67,307 67,3	Rent and administration			_													
Travel Website design and maintence General and Administrative General Ge	Research and Development	22,260	25,232	32,267	8,604	9,273	11,382	12,067	41,326	38,905	31,593	25,655	20,834	16,918	13,739	11,157	9,060
Website design and maintenee B. 847 5, 5857 9, 205 2, 215 3, 185 3, 203 3, 317 13, 320 40,000 75,000 85,000 85,000 86,007 86,970 87,839 68,316 Constraint expenses 31,237 31,085 41,474 11,519 12,459 15,284 15,384 54,447 78,905 178,000 1	Salaries and wages																
Seneral and Administrative S. 847 S. 857 9.205 2.915 3.185 3.003 3.317 3.320 4.0,000 75.000 65.000 65.050 66.307 66.970 67.930 66.970 67.930 69.316 60.970 67.930 69.316 69.970 67.930 69.970 69.970 67.930 69.316 69.970 67.930 69.316 69.970 67.930 69.316 69.970 67.930 69.316 69.970 67.930 69.316 69.970 67.930 69.316 69.970 67.930 69.316 69.970 67.930 69.316 69.970 67.930 69.316 69.970 67.930 69.316 69.970 67.930 69.316 69.970 67.930 69.970 67.930 69.316 69.970 67.930 69.970 67.930 69.970 67.930 69.970 67.930 69.970 67.930 69.970 67.930 69.970 69.9	Travel																
Operating excesses 31,287 31,088 41,474 11,519 12,459 15,284 15,384 16,584 78,908 105,944 90,657 309,700 344,975 207,764 338,239 372,886 372,887 309,700 344,975 207,764 338,239 372,887 309,700 344,975 309,764 309	Website design and maintence																
Coper Laces Lace	General and Administrative																
Coper Margin																	
Chet income (expense) 2,466 Research and Development incentive 299 Research and Development incentive													2,686,721	3,262,062	3,157,826	3,629,857	4,015,474
Research and Development incentive interest and financing fees 207			NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	1	1	1	1	1
Interest and financing fees						692	004		692								
Accretion of debt discount Change in fair value of derivative flability Debt conversion expense (42) Loss on settlement of accounts payable Loss of acco					8					(25)	(25)	(25)	(25)	(25)	(25)	(25)	(25)
Change in fair value of derivative liability Debt conversion expense Loss on settlement of accounts payable Loss on extinguishment of debt Foreign exchange gain (loss) Financing related charges and adjustments Other non-operating income (expense) 2,894 - 2,129 180 - (75) (25) (25) (25) (25) (25) (25) (25) (2					ŭ	200			(20)	(20)	(20)	(20)	(20)	(20)	(20)	(20)	(20)
Debt conversion expense Loss on settlement of accounts payable Loss on settlement of accounts payable Loss on settlement of debt Foreign exchange gain (loss) Cher non-operating income Non-operating																	
Loss on extinguishment of debt Foreign exchange gain (loss) Cher non-operating income Non-operating income (expense) Cher non-operating income Non-operating income (expense) Cher non-operating income (expense) Cher non-operating income Scale (a) Comparison of the		(42)															
Foreign exchange gain (loss) Financial Expenses, Net F																	
Financial related charges and adjustments Other non-operating income (expense) 2,894 - 2,129 180 - (75) (25) (25) (25) (25) (25) (25) (25) (2				l								l					
Other non-operating income (expense) 2,894				l		(733)	(495)		(733)			l					
Non-operating Income (expense) 2,894 - 2,129 180 - (75) (25) (25) (25) (25) (25) (25) (25) (2									ļ			l					
Financial Income, Net Financial Expenses, Net 2,392 2,		2.894	_	2.129		180		_]	(75)	(25)	(25)	(25)	(25)	(25)	(25)	(25)	(25)
Financial Expenses, Net (28,93) (26,258) (36,918) (10,438) (12,279) (14,080) (12,992) (54,722) (78,931) (78,427) (18,792) 2,686,696 3,262,037 3,157,80 3,629,832 4,015,449 Pretax Margin NM		_,50 .		_,.20				2,392	(,, 0)	(20)	(20)	(20)	(20)	(20)	(20)	(20)	(20)
Pretax Margin NM																	
Income Tax Benefit (Provision) (82) (23) (155) (88) (210) (20) (319) (7,893) (14,117) (5,450) 886,610 1,174,333 1,231,543 1,415,635 1,566,025 1,56	Pretax Income	(28,393)	(26,258)	(36,918)		(12,279)	(14,080)	(12,992)	(54,722)	(78,931)	(78,427)	(18,792)	2,686,696	3,262,037	3,157,801	3,629,832	4,015,449
Tax Rate 0 0 5% 5% 5% 5% 1% 10% 18% 29% 30% 31%					NM												
GAAP Net Income (loss) (28.475) (26,280) (37,074) (10,438) (12,368) (14,290) (12,972) (50,068) (71,038) (64,310) (13,342) 1,800,086 2,087,704 1,926,259 2,214,198 2,449,424 Net Margin NM		(82)	(23)	(155)				(20)	(319)	(7,893)	(14,117)	(5,450)	886,610	1,174,333	1,231,543	1,415,635	
Net Margin NM		0	0		370	070		5%	1%	10%	18%	29%	30%	31%	31%	31%	
GAAP-EPS (0.65) (0.45) (0.53) (0.14) (0.16) (0.18) (0.17) (0.65) (0.89) (0.77) (0.15) 19.98 22.26 19.74 21.81 23.18 Non GAAP EPS (dil) (0.65) (0.65) (0.65) (0.65) (0.65) (0.53) (0.14) (0.16) (0.18) (0.17) (0.65) (0.89) (0.77) (0.15) 19.98 22.26 19.74 21.81 23.18 Wgtd Avg Shrs (Bas) 48,906 58,195 69,869 76,249 77,442 77,442 77,477 77,278 78,172 78,485 78,800 79,115 79,432 79,751 80,070 80,391																	
Non GAAP EPS (dil) (0.65) (0.45) (0.53) (0.14) (0.16) (0.18) (0.17) (0.65) (0.89) (0.77) (0.15) 19.98 22.26 19.74 21.81 23.18 Wgtd Avg Shrs (Bas) 48,906 58,195 69,869 76,249 77,442 77,442 77,472 77,278 78,172 78,485 78,800 79,115 79,432 79,751 80,070 80,391		_						_									
Wgtd Avg Shrs (Bas) 48,906 58,195 69,869 76,249 77,442 77,442 77,977 77,278 78,172 78,485 78,800 79,115 79,432 79,751 80,070 80,391																	
																	105,632

Source: Dawson James estimates, company reports



Risk Analysis

Clinical Trial Risk. Anavex is dependent on the outcome of multiple clinical trials. The failure rates associated with disease conditions such as Alzheimer's are historically very high.

Commercial Risk. Anavex hopes to compete in the CNS markets, which have traditionally been dominated by large pharma and biotechnology companies with deep pockets (funding and resources), which may make it difficult for Anavex to compete unless the molecule is deemed to be truly differentiated.

Financial Risk. Anavex is likely to require additional capital raises before the company can be self-sustaining. There can be no guarantees that the company will be able to raise the needed capital.

Investment Risk. Anavex is a small capital company, which can translate into high volatility and risk for investors. The company has no revenues and is dependent on the clinical progress of its therapeutics.

Intellectual Property. Anavex may face I.P. challenges, forcing the company to defend its patents or itself against claims that the company is infringing on other patents. We do know that the lead product is protected by a composition of matter patent to 2033.


Market Share Risk. The central nervous system (CNS) market is competitive and tends to be dominated by large pharma and large well established biotechnology companies.

Regulatory Risk. Anavex, even with good clinical data, could face extensive delays and other regulatory setbacks.

Companies mentioned in this report:

Important Disclosures:

Price Chart:



Price target and rating changes over the past three years:

Initiated – Buy – July 24, 2019 – Price Target \$16.00

Update - Buy - July 31, 2019 - Price Target \$16.00

Update – Buy – August 7, 2019 – Price Target \$16.00

Update – Buy – September 5, 2019 – Price Target \$16.00

Update – Buy – September 17, 2019 – Price Target \$16.00

Update - Buy - October 24, 2019 - Price Target \$16.00

Update - Buy - December 2, 2019 - Price Target \$16.00

Update – Buy – December 4, 2019 – Price Target \$16.00

Update – Buy – February 4, 2020 – Price Target \$16.00

Update - Buy - February 7, 2020 - Price Target \$16.00

Update – Buy – May 8, 2020 – Price Target \$16.00



Update – Buy – May 22, 2020 – Price Target \$16.00

```
Update – Buy – June 16, 2020 – Price Target $16.00
Update – Buy – July 1, 2020 – Price Target $16.00
Update – Buy – October 15, 2020 – Price Target $16.00
Update – Buy – November 6, 2020 – Price Target $16.00
Update – Buy – December 15, 2020 – Price Target $16.00
Price Target Change - Buy - February 19, 2021 - Price Target $16.0 to $19.00
Update – Buy – April 5, 2021 – Price Target $19.00
Update – Buy – April 12, 2021 – Price Target $19.00
Update - Buy - May 19, 2021 - Price Target $19.00
Update – Buy – June 8, 2021 – Price Target $19.00
Price Target Change – Buy – June 21, 2021 – Price Target $35.00
Update - Buy - June 28, 2021 - Price Target $35.00
Update - Buy - October 27, 2021 - Price Target $35.00
Update – Buy – November 24, 2021 – Price Target $35.00
Update – Buy – January 11, 2022 – Price Target $35.00
Update - Buy - February 1, 2022 - Price Target $35.00
Update – Buy – February 4, 2022 – Price Target $35.00
Update – Buy – February 10, 2022 – Price Target $39.00
Update – Buy – June 15, 2022 – Price Target $39.00
Update - Buy - August 2, 2022 - Price Target $39.00
Update - Buy - August 9, 2022 - Price Target $39.00
Update – Buy – October 18, 2022 – Price Target $39.00
Update – Buy – November 8, 2022 – Price Target $39.00
Update – Buy – November 28, 2022 – Price Target $39.00
Update – Buy – November 30, 2022 – Price Target $39.00
Update – Buy – December 5, 2022 – Price Target $39.00
Update – Buy – February 2, 2023 – Price Target $39.00
Update – Buy – February 7, 2023 – Price Target $39.00
```

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the subject company(s). The Firm has NOT engaged in investment banking relationships with AVXL in the prior twelve months, as a manager or co-manager of a public offering and has NOT received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has not received other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of January 30, 2023, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

Information about risks can be found in the "RISK ANALYSIS" section of this report.



The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Rating Definitions:

- 1) **Buy**: The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) Neutral: The analyst believes the price of the stock is fairly valued for the next 12-18 months:
- 3) **Sell**: The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Current as of 30-Jan-23

	Company		Investment	
	Coverage		Banking	
				% of
Ratings Distribution	# of Companies	% of Total	# of Companies	Totals
Market Outperform (Buy)	23	70%	1	4%
Market Perform (Neutral)	9	27%	2	22%
Market Underperform (Sell)	1	3%	0	0%
Total	33	100%	3	9%

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.